Log In


Pain-Free Is Freedom!

AVACEN (Advanced VAscular Circulation ENhancement) Medical provides FDA Cleared, noninvasive, drug-free over-the-counter pain relief and wellness devices, as well as diagnostics for cardiovascular disease and stress. The company has raised $4 million, sold over 9,000 devices, and has safely completed over 22 million treatments to date.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

$232,363.77 Raised


Pain is the #1 reason for medical visits, with up to 116 million people in the US and 30% of the global population suffering from chronic pain. AVACEN is helping to solve this problem without the use of drugs or other invasive treatments. Our FDA 510(k) Cleared family of Class II medical devices use a patented thermotherapy platform technology to noninvasively increase blood flow in approximately 10 billion of the body’s smallest blood vessels.

AVACEN recently launched its 3rd-generation family of fully developed, high-demand, unique consumer and practitioner products into the expanding wellness market that grew to $4.4 trillion globally in 2022.

The AVACEN team is backed by successful leaders who have helped the company secure 17 patents and complete 10 pilot studies all supporting billion-dollar market opportunities such as chronic pain, type 2 diabetes, wound healing, fibromyalgia, and opioid addiction.

*Market information provided by (source)


The Truly Unique Solution for Chronic Pain & Improved Wellness 

AVACEN® is an innovative, noninvasive medical device that warms your body from the inside out, unlocking positive patient outcomes. AVACEN Medical is a leader in FDA-Cleared pain relief and wellness solutions, and is combating the global epidemic of chronic pain. With up to 116 million sufferers in the U.S. alone, the company offers drug-free, noninvasive over-the-counter pain relief.  

THE Problem & OUR Solution

Reimagining The Pain Relief & Wellness Journey 

AVACEN Medical has set out to tackle the pervasive problem of pain that plagues millions worldwide. With pain being the primary reason for medical visits, the need for effective and safe solutions is undeniable. Traditional approaches often rely on opioids, which come with significant risks and contribute to the ongoing epidemic. 

AVACEN Medical offers a one-of-a-kind alternative. By leveraging a patented method that combines heat and negative pressure to enhance systemic microcirculation, their drug-free, noninvasive, over-the-counter devices provide relief without the side effects of opioids. With over 9,000 devices field tested and sold, and an impressive track record of over 22 million treatments without adverse events, AVACEN Medical is offering a safer alternative to pain management. They're even exploring a new franchise concept called Soothe, empowering licensees to establish their own treatment centers.

The Market & Our Traction

Gaining Momentum, Earning Praise

AVACEN Medical is altering the traditional approach to pain management by offering drug-free, noninvasive solutions in response to the opioid crisis and concerns over pharmaceutical side effects. With an astounding 116 million chronic pain sufferers in the U.S., AVACEN Medical addresses the pressing need for alternative treatments. The company's traction is remarkable, with revenue surging from $850K in 2018 to an impressive $4.8 million in 2022. As AVACEN Medical explores new clinical applications in diabetes, fibromyalgia, and wound care, we believe the potential for further revenue growth is substantial.

Supported by 17 patents and counting, AVACEN Medical's state-of-the-art technology is backed by robust intellectual property covering a range of therapeutic uses. The company has earned industry recognition, including being named the Patient Centric Pain Management Technology of the Year in 2022 and securing a spot as a Top 10 Pain Management Device Company. AVACEN Medical's success extends to its international e-commerce initiatives, including Amazon storefronts, and a dedicated sales team of over 250 independent US distributors.

Since its inception, AVACEN Medical has raised $4 million, with an impressive 75% plus of funding directly sourced from customers. With revenues exceeding $20 million to date and consistent cash flow positivity since Q4 2018, the company believes it demonstrates financial stability. Moreover, AVACEN Medical's commitment to innovation is evident through the recent launch of a third-generation technology platform, a new FDA-Cleared cardiac diagnostic, and ongoing development of three additional products for the hospital market. With a distinguished leadership team, global presence, and a track record of success, AVACEN Medical is poised to spearhead the transformative pain management and perioperative market.

Why Invest

A Prescription for Success 

Now’s the time to be part of a whole new approach to pain management with AVACEN Medical. With a massive market size and increasing demand for drug-free solutions, AVACEN Medical is uniquely positioned to combat the opioid epidemic and cater to the needs of nearly 116 million chronic pain sufferers in the U.S. alone. The company’s cutting-edge, FDA-Cleared technology has already gained recognition and success, with multiple patents and awards. As AVACEN expands into new clinical indications and international markets, we believe the potential for growth is significant.

Invest in AVACEN Medical today, and join us in transforming the future of pain relief and wellness!


6451 El Camino Real, Suite C
Carlsbad, CA 92009

AVACEN (Advanced VAscular Circulation ENhancement) Medical provides FDA Cleared, noninvasive, drug-free over-the-counter pain relief and wellness devices, as well as diagnostics for cardiovascular disease and stress. The company has raised $4 million, sold over 9,000 devices, and has safely completed over 22 million treatments to date.


Anthony Shimkin

Anthony Shimkin

CEO, President, Director

25 years of Fortune 500 and startup executive experience in sales, marketing, strategy and business development in medical devices, diagnostics, and HCIT. Throughout his extensive career, Mr. Shimkin held key marketing and innovation leadership roles at several notable companies, including Qualcomm, where he served as senior director of marketing and later, senior director of business development. Before that, he held senior executive positions at Lantronix, Quidel, Cardinal Health, Alaris Medical Systems and Neoforma. He also led the health care equity research team at Wedbush Securities and consulted for leading life sciences companies including Abbott, Boston Scientific, Genentech, Roche and Sanofi. Anthony received his M.B.A. from Boston University, a M.A. from Boston University School of Medicine, a M.S. from the University of San Diego, and a B.A. from Boston University.

Thomas Muehlbauer

Thomas Muehlbauer

Chairman, President, Co-Founder, Product Inventor, and R&D Head

Fortune 500 senior executive experience with over 40 years of CEO and startup skills including acquisitions, capital formation and public market transitions. Prior to founding AVACEN in 2009, Mr. Muehlbauer started an Internet company which was sold to a publicly traded company, bringing a return to founding investors of over 180% in 2 years. As a hands-on investor, he engineered the startup growth and sale of World View, International, providing multimillion dollar returns to shareholders in less than a three-year period.

Danielle Forsgren

Danielle Forsgren

CMO, Co-Founder, and Board Member

Danielle has over 40 years of experience in sales and marketing. She has extensive theatre, radio, public speaking and TV experience including multiple appearances on QVC. As the Company’s top salesperson and Chief Marketing Officer, she is currently developing several strategic initiatives to globally expand sales. Her efforts of the last 3 years have placed the Company on the INC. 5000 list of fastest growing companies in the US. She studied at International University and the University of San Diego.

 Tom Nauman

Tom Nauman

Chief Compliance Officer

Tom Nauman is a Quality, Regulatory, and Operations leader with over 30 years of Fortune 500 and startup experience in medical devices and biotechnology. With a B.S. in Industrial Engineering from Iowa State University, Tom is also a registered Professional Engineer in California and had ASQ certifications for both Quality Engineering and Manager of Quality and Operational Excellence. 

Rhonda Migliaccio

Rhonda Migliaccio

CFO & VP Administration

35+ years of experience in Finance focusing on business development, international trade, and business relations. Fortune 100 company and startup experience. B.A. The University of Wyoming.

James "Jim" Wangler

James "Jim" Wangler

Board Member & Investor

Jim’s former experience includes being a President and CEO, in addition to extensive engineering and engineering management experience. He was President and CEO of MAXIM Systems until the company was sold in December 2007 to Accenture. Prior to MAXIM, Mr. Wangler served as Chief Engineer for the ISR Directorate of SPAWAR Headquarters, where he also served as the Program Manager for a $200 million Space Surveillance program. He received his M.S. from San Diego State University.

Donald Miller

Donald Miller

Board Member

Mr. Miller, a former Naval officer, was co-founder and Sr. V.P. of SeQual Technologies, a San Diego based medical device company. He was also an early-stage investor, Board member, and CFO for numerous companies in San Diego. He received his B.S. in Business Administration from the University of Kansas, and a M.S. in Finance from San Diego State University.

Fredrick Waid

Fredrick Waid

Board Member

Fred focuses primarily in the areas of trust and estate administration, real estate, banking, and corporate governance matters. He serves as a trustee, executor and special administrator of complex trusts and estates, by private and court appointment. Fred has been appointed by state and federal courts as a receiver, special servicer and interim corporate officer. He is a graduate of Baylor Law School and Brigham Young University.

Hamid Khorramian

Hamid Khorramian

Board Member/Investor

Hamid currently acts as an executive consultant and advisor to various Fortune 100 companies and funded startups. He works closely with C-level leaders and board members focusing on lean manufacturing, strategic planning and effective leadership to help harvest a winning culture that’s conducive to reaching long-term KPIs. After working in a leadership role at Steelcase for over 20 years, he retired as Global Senior Vice President. During his time at Steelcase, he created and headed a project that reduced the company’s manufacturing footprint by 65% (9 million square feet), while increasing output by 200% and improving overall customer satisfaction.


AVACEN Medical
Nov 22, 2023
$10k - $1.24M
Common Stock
Common Stock

Maximum Number of Shares Offered subject to adjustment for bonus shares

Most Recent Fiscal Year-End

Prior Fiscal Year-End

Total Assets



Cash & Cash Equivalents



Accounts Receivable



Short-Term Debt



Long-Term Debt



Revenue & Sales



Costs of Goods Sold



Taxes Paid



Net Income



*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.

Voting Rights of Securities Sold in this Offering

Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.

Investment Incentives and Bonuses*

Loyalty Bonus | 10% Bonus Shares

As you have previously invested in AVACEN, Inc., you are eligible for additional bonus shares. Receive 10% bonus shares in AVACEN's current offering on StartEngine if you've (i) previously invested in this issuer, (ii) reserved shares formally through the issuer's Test the Waters campaign on StartEngine; or (iii) indicated interest by signing up to receive news regarding the offering on AVACEN's domain. 

Note: Loyalty Bonus is awarded via investor email address and investors who qualify for this bonus in multiple ways will receive maximum 10% bonus shares from the Loyalty Bonus.

Combo Perks

Super Early Bird Tier 1

Invest $1,000+ within the first 5 days and receive 5% bonus shares.

Super Early Bird Tier 2

Invest $5,000+ within the first 5 days and receive 10% bonus shares.

Super Early Bird Tier 3

Invest $10,000+ within the first 5 days and receive 15% bonus shares.

Super Early Bird Tier 4

Invest $20,000+ within the first 5 days and receive 20% bonus shares.

Super Early Bird Tier 5

Invest $40,000+ within the first 5 days and receive 25% bonus shares.

Early Bird Tier 1

Invest $1,000+ within the first 10 days and receive 3% bonus shares.

Early Bird Tier 2

Invest $5,000+ within the first 10 days and receive 5% bonus shares.

Early Bird Tier 3

Invest $10,000+ within the first 10 days and receive 10% bonus shares.

Early Bird Tier 4

Invest $20,000+ within the first 10 days and receive 15% bonus shares.

Early Bird Tier 5

Invest $40,000+ within the first 10 days and receive 20% bonus shares.

Amount-Based Perks

$1,000+ | Tier 1

Invest $1,000+ and receive a $1,000 discount (coupon code) applicable to the purchase of any AVACEN Medical device.

$5,000+ | Tier 2

Invest $5,000+ and receive a $2,000 discount (coupon code) applicable to the purchase of any AVACEN Medical HOME XL device.

$10,000+ | Tier 3

Invest $10,000+ and receive a $5,000 discount (coupon code) applicable to the purchase of any AVACEN Medical device PLUS 5% bonus shares.

$20,000+ | Tier 4

Invest $20,000+ and receive a $5,000 discount (coupon code) applicable to the purchase of any AVACEN Medical device PLUS 10% bonus shares.

$40,000+ Tier 5

Invest $40,000+ and receive a $5,000 discount (coupon code) applicable to the purchase of any AVACEN Medical device PLUS 15% bonus shares.

*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

AVACEN will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. Owners' Bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $1.00 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $100. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owners' Bonus and the Loyalty Bonus in addition to the aforementioned bonus.

Irregular Use of Proceeds

We will not incur any irregular use of proceeds.



AVACEN Medical was at RAADfest!

AVACEN's Exciting Presence at RAADfest: 

Advancing Wellness and Longevity!

RAADfest is for individuals who are seeking longevity solutions and the future of unlimited health! We were able to connect with entrepreneurs, researchers, and practitioners, learn more about the future of wellness, and share how our devices can contribute to a healthier life.

Invest in AVACEN today!


Owners bonus
Stack Owner's Bonus & Rewards!

Members get an extra 10% shares in addition to rewards below!


Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into AVACEN Medical.


Earn 10% Bonus Shares

Earn 10% bonus shares in this investment and all eligible investments for an entire year. If you are not already an Owners bonus holder, you can join now, for $275, billed annually.


Tier 1

Invest $1,000+ and receive a $1,000 discount (coupon code) applicable to the purchase of any AVACEN Medical device.


Tier 2

Invest $5,000+ and receive a $2,000 discount (coupon code) applicable to the purchase of any AVACEN Medical HOME XL device.


Tier 3

Invest $10,000+ and receive a $5,000 discount (coupon code) applicable to the purchase of any AVACEN Medical device PLUS 5% bonus shares.


Tier 4

Invest $20,000+ and receive a $5,000 discount (coupon code) applicable to the purchase of any AVACEN Medical device PLUS 10% bonus shares.


Tier 5

Invest $40,000+ and receive a $5,000 discount (coupon code) applicable to the purchase of any AVACEN Medical device PLUS 15% bonus shares.



David Amin

9 days ago

$75M valuation on a paltry profit. Comeptition is ready so what is the exit strategy ?



Richard Koch

24 days ago

I'm a chronic pain patient. When I lived in Carlsbad, for 15 years, Pacific Pain in Oceanside were my pain docs who implanted a pain pump. Fast forward about a decade and I'm recovering from 7 fusions in C to T spine. Forgive me if I'm a tad skeptical. 1. Can I assume you're dealing with pain doctors who are actually anesthiologists with certificates in pain management? You know, honest to God pain doctors? Not just somebody with a shingle out that has the word "pain" in the business name? 2. I've been tossing narcotics down my neck since 1991. I've been through some bizarre compounds in my pump, including Prialt (bad juju). This would therapy put all that nonsense to a stop? (Maybe I should ask "could it?" I've gotta manage expectations.) 3. After over thirty years, you're telling me this REALLY works? For someone like me? Or simply for the routine aches and pains that normal people deal with? 4. All that said, I'd love to investing a magic bullet. I've got a pump refill today, so what should I ask my pain doc? I'd like to pose some hypothetical questions to him........ Just askin'




2 months ago

I am investor #133. I just tried Avacen for the first time last week and really liked what I saw and what I heard from distributor Neil Myers here in Orange County, California. I am hopeful that this could be the solution to my 15 years of chronic pain and inflammation, and I look forward to purchasing a device and becoming a distributor. You have written in this pitch that you will use the funds raised via StartEngine (so far around $200,000 less whatever StartEngine takes) to 1. complete your studies on Fibromyalgia, Type II Diabetes and Wound Healing, 2. pursue additional clinical indications for AVACEN devices, 3. continue developing devices that will help treat pain, while you work toward additional clinical indications, 4. continue to acquire devices (like the recent 100% acquisition of CATHHSTA) to reduce pain, improve cardiac health, and enhance wellness. That's a hell of a lot of things to do with very little money. What will be your order of priority, and how much of the raise will you allocate to each priority?



Cayla Donohoue

3 months ago

Highly recommend using an AVACEN device, especially if you're pregnant! I suffered from sciatic nerve pain during my second trimester and received instant relief by using my device 4x a day. As a result, that sciatic nerve was gone completely for the rest of my pregancy. Our baby even came out with A LOT of blonde hair on her head too, and we credit that to the circulation she was getting while I was using the device religiously during my pregnancy. When we got the opportunity to invest in AVACEN, it was a no-brainer. We are happy to be investors with this incredible, life changing, device.



Chad Donohoue

3 months ago

Absolutely love our Avacen device! Great product with amazing results for our whole family! My mom began using it while on chemo and it completely took away the main side effect of neuropathy and really helps her back pain, my wife uses it for stress relief, and I use it to improve my circulation and overall health! So thankful for this opportunity to invest!



Grigore Hreniuc

3 months ago

According to your website, the company has been in business for 15 years. Where do the devices are manufactured? The cost of $5K-$10K for a device is high and comes with only 12 months warranty. The average consumer can't afford the price. Does Medicare cover any of your devices? I notice your device is FDA-cleared. Do you have plans to have this device FDA-approved?



John Sklarosky

3 months ago

Hello. Could you explain the high valuation? Just seems a bit high.




Cancel anytime before 48 hours before a rolling close or the offering end date.



We want you to succeed and get the most out of your money by offering rewards and memberships!


Your info is your info. We take pride in keeping it that way!


Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.


Get To Know Us

Our Team



Important Message


www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.
Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRASIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

Investment opportunities posted and accessible through the site are of three types:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.
By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information

(800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.

StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.

StartEngine Marketplace

The availability of company information does not indicate that the company has endorsed, supports, or otherwise participates with StartEngine.

None of the information displayed on or downloadable from www.startengine.com (the 'Website') represents a recommendation, offer, or solicitation of an offer to buy or sell any security. It also does not constitute an offer to provide investment advice or service. StartEngine does not (1) make any recommendations or otherwise advise on the merits or advisability of a particular investment or transaction, or (2) assist in the determination of fair value of any security or investment, or (3) provide legal, tax, or transactional advisory services.

All investment opportunities are based on indicated interest from sellers and will need to be confirmed.

Investing in private company securities is not suitable for all investors. An investment in private company securities is highly speculative and involves a high degree of risk. It should only be considered a long-term investment. You must be prepared to withstand a total loss of your investment. Private company securities are also highly illiquid, and there is no guarantee that a market will develop for such securities. Each investment also carries its own specific risks, and you should complete your own independent due diligence regarding the investment. This includes obtaining additional information about the company, opinions, financial projections, and legal or other investment advice. Accordingly, investing in private company securities is appropriate only for those investors who can tolerate a high degree of risk and do not require a liquid investment.

StartEngine Marketplace (“SE Marketplace”) is a website operated by StartEngine Primary, LLC (“SE Primary”), a broker-dealer that is registered with the SEC and a member of FINRA and the SIPC. StartEngine Bulletin Board ("SE BB") is a bulletin board platform that advertises interest in shares of private companies that previously executed Reg CF or Reg A offerings. SE BB enables shareholders to communicate interest in potential sales of shares in private companies and investors to discover, review, and potentially invest in private companies. As a bulletin board platform, SE BB provides a venue for investors to access information about private company offerings and connect with potential sellers. SE BB is distinct and separate from StartEngine Secondary (“SE Secondary”), which is an SEC-registered Alternative Trading System (ATS) operated by SE Primary. SE Secondary facilitates the trading of securities by matching orders between buyers and sellers and facilitating executions of trades on the platform. While a security may be displayed on the bulletin board, these securities will be subject to certain restrictions which may prevent the ability to buy and sell these securities in a timely manner, if at all. Even if a security is qualified to be displayed on the bulletin board, there is no guarantee an active trading market for the securities will ever develop, or if developed, be maintained. You should assume that you may not be able to liquidate your investment for some time or be able to pledge these shares as collateral.